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Solving the molecular structure of hybrid human-porcine factor VIII
through X-ray crystallization
Mikko Sayre, Amanda Weis, Brenna Park-Egan, and Paul C. Spiegel
Department of Chemistry, Western Washington University, Bellingham, WA

Abstract:

Factor VIII (fVIII) is a protein that is involved in the coagulation cascade, a
collection of reactions that is activated by injury and leads to the
formation of blood clots. Deficiencies in fVIII lead to the bleeding
disorder hemophilia A, a condition that occurs in 1 in 5000 births. The
current treatment for hemophilia A is inefficient and costly; however,
there is potential through the use of recombinant hybrid human-porcine
fVIII. Hybrid fVIII shows up to 12-fold higher coagulant activity than
human fVIII, and can retain its activity even in the presence of inhibitory
antibodies. The primary objective of our study is to determine the
molecular structure of full-length hybrid human-porcine fVIII through Xray crystallography. This allows us to see how the protein functions on a
molecular level, along with the details of its interactions with binding
partners. Thus far we have produced crystals of fVIII in complex with IgG
antibodies 3E6 FAB and G99 FAB, along with the TIL’E’ domain of binding
partner von Willebrand factor. These crystals have exhibited limited
diffraction, and we are working towards optimizing crystals to increase
the resolution of the diffraction pattern. The structure of hybrid fVIII has
not yet been studied in detail, and this information could demonstrate
the its viability, bringing us one step closer to a long-term, effective, and
economical treatment of hemophilia.

Methods:

Hybrid fVIII expression and
preparation:
• Hybrid fVIII was prepared by Dr.
Lollar’s lab at Emory University
• To increase expression, the Bdomain was removed and porcine
sequences were added to the A1
and ap-A3 domain (Figure 3).6
• To decrease immune response,
porcine sequences were added to
the C1 domain and substitutions
were made in A2 (Figure 3).6
• fVIII complex consists of hybrid fVIII
bound to combinations of
Figure 2. Schematic of the light-chain subunit
antibodies (3E6 FAB and/or G99 FAB) of fVIII with TIL’E’ and IgG antibodies G99 FAB
along with the TIL’E’ domain of the and 3E6 FAB bound.
D’D3 subunit of vWF (Figure 2).
X-ray Crystallography:
• Crystals are produced through hanging drop vapor diffusion (Figure 4).
• Successful crystallization involves extensive modulation of buffers, ionic
strengths, and precipitants.

Background: fVIII and Hemophilia A

Figure 3. Hybrid fVIII gene construct.6 The Bdomain of human fVIII was removed, and
porcine sequences were inserted (shown in
yellow).

Figure 4. The hanging-drop
vapor diffusion
crystallization method.

Results and Future Work:

Figure 1. The Coagulation Cascade.1 When tissue damage occurs, the intrinsic
pathway of the coagulation cascade is activated. fVIII circulates in its inactive form
bound to vWF. Upon activation, vWF is cleaved and fVIIIa acts as a cofactor for fIX.

• fVIII is a heterodimer made up of a heavy chain (with domains A1A2-B) and a light chain (A3-C1-C2).2
• Individuals with hemophilia A have little or no ability to produce
fVIII, and as a result cannot form clots.
• About one half of diagnosed hemophilia A patients have the
severe form of the disease, with less than 1% of normal fVIII.3
• Treatment for hemophilia averages $468,000 per year.4
• Recently, potential has been shown through the use of hybrid
human-porcine fVIII.5
• Hybrid fVIII shows up to 12-fold higher coagulation activity than
human fVIII, and retains activity in presence of inhibitory
antibodies that affect human fVIII.5
• The structure of hybrid fVIII has not yet been studied in detail.
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• Hybrid fVIII + G99 FAB crystals have
diffracted to a resolution of 4-8 Å
(Figure 4a,b).
• Crystals of fVIII complex with various
binding partners have been
produced in several conditions.
• Current goals include modulation of
conditions to produce crystals of
fVIII+TIL’E’+3E6 FAB and fVIII+TIL’E’+
G99 FAB.
• The ultimate goal is to obtain
diffraction results with a resolution
of 1-3 Å.
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Figure 4. Hybrid fVIII complex
crystallization results. a) fVIII+G99 FAB in
0.050 M DL-Malic acid pH 7.0, 12% PEG
3350. b) fVIII+G99 FAB in 0.050 M DL-Malic
acid pH 6.8, 10% PEG 3350 c)
fVIII+TIL’E’+3E6 FAB in 0.1 M BIS-TRIS
propane pH 8.0, 32% PEG 6000. d)
fVIII+TIL’E’+G99 FAB in 0.1 M MES
monohydrate pH 6.0, 22% PEG 400

1) Wuerth, M.E. (2015) Structural Studies of Blood Coagulation Factor VIII in Protein Complexes.
WWU Masters Thesis Collection. Paper 436.
2) Walter, J.D., R.A. Werther, C.M. Brinson, R.K. Cragerud, J.F. Healey, S.L. Meeks, P. Lollar, and
P.C. Spiegel Jr. (2013) Structure of the factor VIII C2 domain in a ternary complex with 2
inhibitor antibodies reveals classical and nonclassical epitopes. Blood. 122:26, 4270-4278.
3) Hoyer, L.W. (1981) The Factor VIII Complex: Structure and Function. Blood, 58, 1-13.
4) Genetics Home Reference [Internet]. Bethesda: U.S. Nat’l Library of Medicine. 2012.
Hemophilia. 17 May 2016. Available at: https://ghr.nlm.nih.gov
5) Lollar, P., E.T. Parker, and P.J. Fay. (1992). Coagulant Properties of Hybrid Human/Porcine
Factor VIII Molecules. J. Biol. Chem. 267:33, 23652-23657.
6) Spencer, H.T., G. Denning, R.E. Gautney, B. Dropulic, A.J. Roy, L. Baranyi, B. Gangadharan, E.T.
Parker, P. Lollar, and C.B. Doering (2011). Lentiviral Vector Platform for Production of
Bioengineered Recombinant Coagulation Factor VIII. Molecular Therapy. 19:2, 302-309

